In a series of 2847 HR+ breast cancer patients, Cheang et al showed how Ki67 was able to discriminate luminal B from luminal A tumors and that this marker was significantly associated with poor disease recurrence-free and disease-specific survival in all adjuvant systemic treatment categories [9]. Here, MKI67 is linked to breast cancer.